AstraZeneca PLC · LSE:AZN
AstraZeneca — Merrill Lynch Pharma Conference 2004
29 slides from AstraZeneca's conference presentation, Sep 21, 2004
Slide 1: Merrill Lynch Pharma Conference
A Merrill Lynch Pharma Conference Mike Rance, VP, Corporate Affairs 21st September 2004
Slide 2: AstraZeneca strategy
AstraZeneca strategy 1999 2004 2008+ Deliver Top-tier financial performance Full potential of growth portfolio Drive Productivity for competitive Sustainable Platform for advantage growth for growth Expand long term Next wave of development projects In-house discovery External collaboration Broaden
Slide 3: 2004 priorities
2004 priorities Continue to build Crestor® into megabrand Drive Oncology portfolio Progress to US market leadership for Nexium® and Seroquel® First launches for Exanta® and register chronic claims Advance development projects Continuous improvement in productivity 2004 EPS range in range of $2. 00 t
Slide 4: Crestor
Crestor® Approved in over 60 markets Over 3 million patients treated Over 10 million prescriptions dispensed globally Efficacy and safety confirmed in the market New NCEP guidelines 4 A
Slide 5: Crestor: STELLAR study
Crestor®: STELLAR study LDL-C lowering across the dose range LDL-C: LS mean change from baseline at week 6 ! "# $ # # $ ## % $ ## ! "# $ % 5 A
Slide 6: Reporting rates of rhabdomyolysis with statin therapy
Reporting rates of rhabdomyolysis with statin therapy Semiannual Reporting Rates for All Reports of Rhabdomyolysis . ! $ ## / 01 0 2 ** )*$ ## *$ ## 0 "# $ # # +$ ## / ) % $ ## & $ ## # ## '( ) # ## & ,- $ ## *$ # # & +&,(-.& & &'' '&'' & '& & '& & '& & & & &'' & & & & & & & (& & & & ‡Global reporti
Slide 7: Reporting rates of fatal rhabdomyolysis with statin therapy
Reporting rates of fatal rhabdomyolysis with statin therapy Semiannual Reporting Rates for All Reports of Fatal Rhabdomyolysis / 01 0 . ! 2 $ ## ** *$ ## 0 )*$ ## "# $ # # / +$ ## % $ ## ) $ ## & # ## ) '( & # ## ,- $ ## *$ # # +&,(-.& & & &'' '&'' & '& & '& & '& & & & &'' & & & & & & & (& & & & ‡Gl
Slide 8: CRESTOR Share
CRESTOR Share 9/ 19 0% 1% 2% 3% 4% 5% 6% 7% 8% 9% /0 10 3 /3 / 10 03 /1 7/ 10 03 /3 1/ 11 03 /1 4/ 11 03 /2 8/ 12 03 /1 2/ 12 03 /2 6/ 03 1/ 9/ 0 1/ 4 23 /0 4 2/ 6/ 0 2/ 4 20 /0 4 3/ 5/ 0 3/ 4 19 NR x Share /0 US Crestor® growth 4 4/ 2/ 0 4/ 4 16 /0 4/ 4 30 /0 T Rx Sh are 5/ 4 14 /0 5/ 4 2 8/ 0 6/ 4
Slide 9: Crestor US Dynamic Share (new and switched patients)
w k1 w e w 19 k3 / 0 5 10 15 20 25 30 35 40 45 50 w 09 e /0 3 03 w / 10 k5 /0 w 17 3 k7 /1 w 0/ e 03 w 31 Market = USC 32110. k9 / w 10 wk e /0 3 11 14/ w 1 1/ wk e 2 03 13 8 /1 w 1 w e2 /03 k1 1/ 5 12 w e /0 3 26 w k1 /21 wk 7 0 /0 3 CRESTOR 19 9/ w 01/ w e k2 23 04 1 /0 w 1/ e 04 NOTE: As Of 06/08
Slide 10: Key brands maintain Share of Voice
Key brands maintain Share of Voice CRESTOR 60% Launch 50% Detail Sh are of Voice 40% TOPROL XL 30% NEXIUM CRESTOR, PCP CRESTOR, Card 20% SEROQUEL 10% RHINOCORT AQUA PULMICORT RESPULES 0% 4 3 3 03 3 03 4 4 03 03 -0 t-0 -0 0 l-0 0 g- v- n- p- c- n- ar b Ju Oc Au No Ju Se De Ja Fe M A Source: IMS IPS (
Slide 11: Nexium US TRx PPI market share
Nexium® US TRx PPI market share 60% Total Prescription Market Share (PPI) 50% 40% 30% 20% 10% 0% 00 01 02 03 04 0 0 0 1 1 1 2 2 2 3 3 3 4 4 -0 l-0 -0 l-0 -0 l-0 -0 l-0 -0 l-0 -0 -0 -0 -0 n- n- n- n- n- pr pr pr pr pr Ju Ju Ju Ju Ju ct ct ct ct Ja Ja Ja Ja Ja A A A A A O O O O Prilosec® Nexium® Preva
Slide 12: US PPI market - TRx extended unit growth trends
US PPI market - TRx extended unit growth trends* Q103 Q203 Q303 Q403 Q104 Q204 June 90% 76% TRx EU Growth % 70% 56% 47% 50% 31% 33% 26% 26% 30% 22% 21% 16% 15% 15% 16% 18% 14% 12% 9% 10% 3% 0% -0.5% -10% -5% -3% -8% -12% -30% -34% -40% -42% -40% -50% PPI Omeprazole PPI ex-omep Nexium® *TRx EU growth
Slide 13: Seroquel
Seroquel® End June MAT $1.709bn H1 04 sales - $936m Atypical market growth continues Seroquel® gaining market share Mix improvement New data • Bipolar depression data (BOLDER Study) – APA ’04 • Efficacy in dementia (STAR Study) – ICAD ‘04 *Source: IMS Health, IMS MIDAS 2003 13 A
Slide 14: US: Trends in Antipsychotics
M A RXs (Millions) T M Ju 0 5 10 15 20 25 30 35 40 45 50 A T l -9 S 8 M ep A T -98 M No A T v- 9 M Ja 8 A n- T 9 M Ma 9 A T r- 9 M 9 50% 50% M ay A -9 T 9 M Ju AT l - 9 S 9 M ep A - T 9 N 9 Source: IMS Health, NPA; NSP M o A v- T 99 M Ja A n-0 T M Ma 0 A T r- 0 M 0 TYPICAL RXs M ay ATYPICAL RXs A -0
Slide 15: Europe: Strong RX growth for atypicals
Europe: Strong RX growth for atypicals 1998 – Q1 2004 : Major Opportunity 45 TYPICAL R xs $3,000 ATYPICAL R xs 40 TYPICAL Sales ($m) ATYPICAL Sales ($m) $2,500 35 Sales (Millions USD) 30 $2,000 Rxs (Millions) 25 62% 80% $1,500 85% 20 15 $1,000 38% 10 20% $500 5 15% 0 $0 MAT MAT MAT MAT MAT MAT MAT M
Slide 16: Seroquel: US NRx in anti-psychotic market
0% 5% 10% 15% 20% 25% 30% 35% Jan-00 Feb-00 Mar-00 Apr-00 Market share May-00 Jun-00 Jul-00 Aug-00 Sep-00 Oct-00 Nov-00 market Dec-00 Jan-01 Feb-01 Mar-01 Apr-01 May-01 Jun-01 Jul-01 Aug-01 Sep-01 Oct-01 Nov-01 Dec-01 Jan-02 Feb-02 Mar-02 Apr-02 May-02 Jun-02 Jul-02 Aug-02 Sep-02 Oct-02 Nov-02 Dec-0
Slide 17: Seroquel Bipolar Mania
Seroquel® Bipolar Mania Change from baseline (YMRS) 0 * p<0.05 ** p<0.01 *** p<0.001 -5 * ** Placebo -10 *** -15 *** *** *** Seroquel® -20 *** *** *** -25 47 14 21 28 42 56 70 84 Day YMRS – Young mania rating scale Sachs et al Bipolar Disorders 2004: 6: 213 17 A
Slide 18: Successful mania launch in Europe
Value Market Share % Value Market Share % 8% 12% 16% 8% 10% 12% 14% Jan-03 Jan-03 Feb-03 Feb-03 Mar-03 Mar-03 Apr-03 Apr-03 May-03 May-03 Jun-03 Jun-03 Jul-03 Jul-03 Aug-03 Source: IMS Health MIDAS Monthly Aug-03 UK Sep-03 Sep-03 Oct-03 Launch Oct-03 Launch Germany Nov-03 Nov-03 Dec-03 Bipolar Mania
Slide 19: Seroquel Bipolar Depression
Seroquel® Bipolar Depression Study Week 0 1 2 3 4 5 6 7 8 0 Mean Change From Baseline (MADRS) Quetiapine 600 mg (n=170) Quetiapine 300 mg (n=172) -5 Placebo (n=169) * -10 * * * * * -15 * * * * * * * * * * -20 MADRS, Montgomery-Asberg Depression Rating Scale *P<0.001 (vs placebo) A ITT, LOCF 19 Calab
Slide 20: Symbicort value share Europe
Symbicort® value share Europe Symbicort® total market share of Fixed Combination in 18 markets of which Symbicort® is launched in 18 30% 25% 20% Market Share 15% 10% 5% 0% 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 Months after launch Source: IMS Health monthly MIDAS & Local
Slide 21: Oncology - progress
Oncology - progress Casodex® - class leader ($478 million +4%CER) • Early prostate cancer Arimidex® - class leader ($357 million +39% CER) • Adjuvant treatment of early breast cancer • 5 year ATAC data later this year Faslodex® - first in class ($49 million) • Launched in first EU markets Iressa® -
Slide 22: Iressa
Iressa® Science and NEJM data - identification of specific predictors of response • EGFR gene mutation in tumor cells • Mutations studied in patients with significant tumor response – other subsets need further analysis • Findings offer opportunity to accelerate first line use ASCO 2004 • Tarceva® v
Slide 23: US EAP 21,000 Patient Analysis: One Year Survival
US EAP 21,000 Patient Analysis: One Year Survival 30% 1.0 Median 1-year At risk (months) survival (%) 21,064 5.3 (95% CI 5.1-5.5) 29.9 (95% CI 28.8-31.1) 0.8 ~ 30% survival at 1 year Proportion event-free Massarelli et al 3rd & 4th line Reference data 0.6 Iressa® IDEAL 1 Iressa® IDEAL 2 Iressa® EAP
Slide 24: Iressa US 'uplift' post mutation data and ASCO
Iressa® US ‘uplift’ post mutation data and ASCO US Prescription trends (TRx / NRx) 10,000 9,000 8,000 7,000 6,000 Rx 5,000 4,000 3,000 2,000 1,000 0 Jun-03 Jul-03 Nov-03 Jun-04 Aug-03 Sep-03 Oct-03 Dec-03 Jan-04 Feb-04 Mar-04 Apr-04 May-04 Monthly New Scripts Monthly Total Scripts Source: IMS NPA 24
Slide 25: Novels continue to transform oncology market
Novels continue to transform oncology market Novels account for 20% of market New ‘science’ delivering and growing 20 Improved molecular biology 18 16 understanding 14 12 $Bn Novels transforming 10 8 oncology market 6 4 2 AZ - Leading pipeline 0 Q1/00 Q1/97 Q1/98 Q1/99 Q1/01 Q1/02 Q1/03 Q1/04 Cytoto
Slide 26: A Reminder....
A Reminder…. Atacand® Toprol XL® Pulmicort Respules® Rhinocort Aqua® Zomig® Merrem® ………………. 26 A
Slide 27: AstraZeneca strategy
AstraZeneca strategy 1999 2004 2008+ Deliver Top-tier financial performance Full potential of growth portfolio Drive Productivity for competitive Sustainable Platform for advantage growth for growth Expand long term Next wave of development projects In-house discovery External collaboration Broaden
Slide 28: Cautionary Statement Regarding Forward-Looking Statements
Cautionary Statement Regarding Forward-Looking Statements In order to utilise the ‘Safe Harbor’ provisions of the United States Private Securities Litigation Reform Act of 1995, AstraZeneca is providing the following cautionary statement. This Interim Report contains forward-looking statements with
Slide 29: 2004 guidance – Q2 update
2004 guidance – Q2 update Strong second half earnings growth anticipated • Continued performance of growth portfolio • Slower growth of R&D and SG&A costs • Strong focus on productivity across the business Some reversal of YTD currency benefits expected Market trends may mitigate outcome Full year t